Lv31
208 积分 2022-07-22 加入
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
4小时前
已完结
The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility
5天前
已完结
From RAS inhibitor resistance to rational combination strategies
8天前
已完结
BRAF oncogenic mutants evade autoinhibition through a common mechanism
9天前
已完结
The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338
17天前
已完结
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
19天前
已完结
C-Met Proto-Oncogene Expression in Benign and Malignant Human Renal Tissues
27天前
已完结
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
1个月前
已完结
Abstract PS1-10-08: Er riptacs drive tumor selective cell death in post-cdk4/6i resistance settings and demonstrate oral efficacy in cdx and pdx models
1个月前
已完结
Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer
1个月前
已完结
皖公网安备34019202002308
